A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

NCT04847557 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults with both heart failure with preserved ejection fraction and obesity to see how it affects their heart-related quality of life.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 731 people

Who can join Ages 40+ · all sexes

Timeline Started 2021-04 · est. completion 2024-07

Where 146 sites · Argentina, Brazil, China, India, Israel, Mexico, Puerto Rico, Russia, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT04847557 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Other

Administered SC

Main thing measured	Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04847557 ↗